China moves to ban export of select biotech platforms while keeping drug licensing open

Chinese Ministry of Commerce announced it is pursuing an export ban on certain biotechnology platforms.

The measure is intended to restrict the types of deals domestic companies can make abroad, reflecting a tightening of trade controls.

Officials indicated that the licensing of pharmaceuticals for export will continue without interruption, suggesting the ban targets only platform technologies rather than finished drug products.

The policy could affect companies that develop or sell gene-editing, cell-therapy or other advanced biotech tools, though the exact scope was not detailed.

Analysts note the move may signal a broader shift in China’s approach to protecting strategic biotech assets while maintaining drug supply flows.